PHE News

Precision for Medicine Acquires Precision Health Economics

Extends Leadership in Health Economics and Outcomes Research With a Focus on Evidence Generation in an Era of Precision Medicine.

Precision for Medicine, a specialized services company supporting next-generation approaches to drug development and commercialization, today announced the acquisition of Precision Health Economics (PHE).


Precision's Ton Teaches At NIH

Precision Associate Director and Senior Research Epidemiologist Thanh Ton has been selected by the National Institutes of Health to teach data management and analysis at the NIH/Fogarty Global Health Program for Scholars and Fellows, to be held July 10-15th in Bethesda, MD.


PHE's Goldman Elected to ISPOR Board of Directors

Precision is proud to announce that founding partner Dana Goldman has been elected to ISPOR's Board of Directors, effective July 1st, 2015. The Board of Directors are elected by ISPOR members – over 9,500 global members were given the opportunity to vote for nominated candidates.


Philipson Quoted in Scientific American worldVIEW

Founding partner Tomas Philipson is quoted in the lead editorial of the 2015 Scientific American worldViEW.


Look for Precision at BIO 2015!

Precision will be looking for you at the 2015 BIO International Convention in Philadelphia, PA! Our thought leaders will be participating in a number of panels.

  • Academic Insights at

    the Speed of Business

  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Medicine, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

  • Academic Insights at

    the Speed of Business